Search

Search Constraints

You searched for: Author/Creator Maher, Vincent

Search Results

1. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (November 2019)

3. Corrigendum to "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk" [Atherosclerosis 290 (2019) 140–205]. (February 2020)

4. Dynamic changes of the composition of plasma HDL particles in patients with cardiac disease: Spotlight on sphingosine‐1‐phosphate/serum amyloid A ratio. (12th December 2017)

5. Erratum to "2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk" [Atherosclerosis 290 (2019) 140–205]. (January 2020)

6. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. (28th August 2020)

7. Evaluation of the effectiveness of a phase three specialised heart failure cardiac rehabilitation programme on cardiovascular risk factor profile. (2nd August 2021)

9. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Issue 10312 (6th November 2021)

10. Impact of Ivabradine on Central Aortic Blood Pressure and Myocardial Perfusion in Patients With Stable Coronary Artery Disease. Issue 6 (December 2015)